Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 3,541-3,552 of 4,306
Drug study icon
CompletedNCT00791713

The Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

This study is completed. It focuses on Schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 55 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT00791401

Safety study of Pharmacokinetics of ER OROS Paliperidone in Schizophrenia

This study is completed. It is testing Pharmacokinetics of ER OROS Paliperidone for Schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 75 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT00791284

Safety study of pharmacokinetics of Paliperidone in Schizophrenia

This study is completed. It is testing pharmacokinetics of Paliperidone for Schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 75 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT01429740

Safety study of Single Doses Of PF-05180999 in Schizophrenia

This study is completed in the United States. It is testing Single Doses Of PF-05180999 for Schizophrenia.

In New Haven
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT00216632

Treatment Success for Schizophrenia

This study is completed. It is testing treatment Success for Schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugOver 18 Years
Countries
Sponsor
Janssen Pharmaceutica N.V., Belgium
Condition
Schizophrenia
Drug study icon
CompletedNCT02935725

PharmacoMRI Effects of AUT00206 in Healthy Males

This study is completed in the United Kingdom. It is testing pharmacoMRI Effects of AUT00206 for Schizophrenia.

In London
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 45 Years
Countries
United Kingdom
Sponsor
Autifony Therapeutics Limited
Condition
Schizophrenia
Drug study icon
CompletedNCT01050582

Safety study of safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Schizophrenia

This study is completed in the United States, in Belgium, in Germany, .... It is testing safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation for Schizophrenia.

Multiple locations, including San Francisco
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, BipolarityDrugFrom 8 Years to 16 Years
Countries
United States, Belgium, Germany, ...
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia, Bipolarity
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.